Viking Therapeutics VKTX 深 滬
已收盤 08-07 16:00:00 美东时间
34.26
+0.960
+2.88%
華盛通- 最 高34.33
- 今 開33.82
- 成交量 140.25万股
- 最 低 33.21
- 昨 收 33.30
- 總市值 39.97亿
- 52周最高 43.15
- 市盈率 靜 --
- 換手率 1.20%
- 52周最低 22.959
- 委 比 -66.39%
- 總股本 1.17亿
- 歷史最高 99.41
- 量 比 0.83
- 振 幅 3.36%
- 歷史最低 0.88
- 每 手 1
- 風險率 4.01%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Eli Lilly and Co Stock (LLY) Moved Up by 6.32% on Aug 5: A Full Analysis
• Eli Lilly shares rose following strong quarterly earnings and increased full-year financial guidance. • Expanding clinical applications for metabolic drugs have broadened the company’s total addressable market. • Increased manufacturing capacity has improved supply, supporting sustained demand for key pharmaceutical products.
08-05 14:15
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $114
Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $107 to $114.
07-30 23:56
财报速睇 | Viking Therapeutics 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损1.28亿美元，同比亏损扩大95.3%
华盛资讯7月30日讯，Viking Therapeutics公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损1.28亿美元，同比亏损扩大95.3%。
07-30 05:51
财报速睇 | Viking Therapeutics 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损1.28亿美元，同比亏损扩大93.9%
华盛资讯7月30日讯，Viking Therapeutics公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损1.28亿美元，同比亏损扩大93.9%。
07-30 04:30
Viking Therapeutics Q2 EPS $(1.10) Beats $(1.25) Estimate
Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of $(1.25) by 12 percent. This is a 89.66 percent decrease over losses of $(0.58) per share from the same period last year.
07-30 04:08
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX...
07-22 04:41
Here’s How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 10 Years
Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 10 years by 26.85% on an annualized basis producing an average annual return of 40.15%. Currently, Viking Therapeutics has a market capitalization of $4.47 billion. Buying $1000 In VKTX: If an investor had bought $1000 of VK...
07-11 00:18
Chip Bloodbath Hits Nasdaq 100 As South Korea Plunges: Stock Market Today
U.S. stocks splintered Tuesday as a violent global sell-off in semiconductor shares hammered the Nasdaq, even as a rotation into defensive sectors and small caps kept the Dow Jones in positive territory through midday trading. • SanDisk stock is showing notable weakness. What’s weighing on SNDK shar...
06-24 00:45
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
